← ANALYST RATINGS · TIPRANKS
Caribou Biosciences (CRBU): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy4 Hold0 Sell
Ratings of 6 analysts in the last 3 months12-month forecast
Based on 6 price targets given in the last 3 months, the average target is $3.75, the highest $8.00, the lowest $1.00. The average is +699.6% from the last price of $0.47.
Analyst ratings 10
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.46 → $0.47+1.9% | Sell | +0.4% | Downgrade | 13.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.45 → $0.46+3.1% | Sell | −1.1% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.46 → $0.47+3.7% | Hold | +1.1% | Upgrade | 13.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.43 → $0.44+2.5% | Sell | −5.3% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.45 → $0.47+3.6% | Sell | −0.6% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.46 → $0.47+2.0% | Sell | −0.6% | Reiterated | 13.10.26on TipRanks 01:05 | — | |
| Robert Burns★★★★★★★★★★#272 · hits 52% · avg +25.9% | H.C. Wainwright | — | Hold | — | Downgrade | 08.10.26on TipRanks 06:20 | −21.6%next day −5.0% · 5 days −3.3% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $10.00 → $1.00−90.0% | Hold | +113.2% | Downgrade | 06.10.26on TipRanks Oct 7 05:11 | −5.2%next day −45.4% · 5 days −58.5% | ↗ |
| Daina Graybosch★★★★★★★★★★#12254 · hits 39% · avg −7.8% | Leerink Partners | $4.00 → $1.00−75.0% | Hold | +113.2% | Downgrade | 06.10.26on TipRanks Oct 7 05:11 | −5.2%next day −45.4% · 5 days −58.5% | ↗ |
| Leah R. Cann★★★★★★★★★★#11464 · hits 38% · avg −2.6% | Brookline Capital Markets | — | Hold | — | Downgrade | 06.10.26on TipRanks 19:10 | −45.4%next day −21.6% · 5 days −24.5% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | $6.00 → $5.00−16.7% | Buy | +966.1% | Reiterated | 14.08.26on TipRanks 07:10 | −1.7%next day −0.2% · 5 days +6.4% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $8.00 | Buy | +1,605.8% | Assigned | 13.08.26on TipRanks Aug 14 05:35 | −6.0%next day −1.7% · 5 days +2.0% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $11.00 → $13.00+18.2% | Buy | +2,671.9% | Reiterated | 09.03.26on TipRanks Mar 10 01:10 | +7.4%next day +3.2% · 5 days −3.7% | ↗ |
| Asthika Goonewardene★★★★★★★★★★#5130 · hits 41% · avg +2.0% | Truist Financial | $7.00 | Buy | +1,392.5% | Reiterated | 09.03.26on TipRanks 07:30 | +7.4%next day +3.2% · 5 days −3.7% | ↗ |
| Unknown Analyst | Leerink Partners | $4.00 | Buy | +752.9% | Reiterated | 06.03.26on TipRanks 11:00 | +7.7%next day +7.4% · 5 days +4.8% | ↗ |
| William Maughan★★★★★★★★★★#1398 · hits 46% · avg +16.2% | Clear Street | $13.00 | Buy | +2,671.9% | Reiterated | 06.03.26on TipRanks Mar 5 17:30 | +7.7%next day +7.4% · 5 days +4.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Caribou Biosciences
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.67 at a price of $1.27 (+503.7%); now: $3.75 at $0.47 (+699.6%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 15 | 10 | 9 | 6 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · Healthcare
About Caribou Biosciences
- CEO: Rachel E. Haurwitz
- Employees: 97
- 2929 7th Street, Berkeley, CA, 94710, US
- cariboubio.com
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies. These cutting-edge treatments are engineered to address both hematologic malignancies (blood cancers) and solid tumors, serving patients across the United States and internationally. Among its primary therapeutic candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy currently undergoing Phase 1 clinical trials for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma. Caribou Biosciences is additionally developing CB-012, an allogeneic anti-CD371 CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, along with CB-020, an allogeneic CAR-NK cell therapy aimed at solid tumors. The company also maintains a collaborative agreement with AbbVie Manufacturing Management Unlimited Company for the joint advancement of CAR-T cell therapies. Founded in 2011, Caribou Biosciences' headquarters are located in Berkeley, California.
Data from the stock’s TipRanks forecast page, read 106 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗